Deals Of The Week: Medco/United BioSource, Aspen/Sigma, Biogen/Knopp ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Already partnered in RNA interference with Alnylam, Novartis pays $10 million for an option to Quark's QPI-1002.
Big biotech pays $80 million to Knopp Biosciences for worldwide license to dexpramiprexole.
TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division